The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with metastatic breast cancer (MBC). 51 patients with MBC received oral vinorelbine and capecitabine. The safety profile was analyzed through NCI-CTCAE v3.0 and response was evaluated using RECIST criteria. The overall response rate was 37.2%: there were four complete responders (8%) and fifteen partial responders (29.4%); practically all the responders were patients previously treated with anthracyclines and taxanes. Sixteen patients (31.3%) experienced stable disease. The clinical benefit rate was 68.5%. The median time to progression was 8 months (range 2-43; 95% Cl: 6-10.8). Vinorelbine in combination with capecitabine is an effective and safe schedule for patients with MBC especially after pretreatment with anthracycline/taxane-based regimens. The clinical benefit suggests that this may be a promising schedule in the MBC initial treatment.
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer / DI SERI, Marisa; De Sanctis, R.; Quadrini, S.; Adua, D.; Stumbo, L.; Del Signore, E.; Gori, B.; Grassi, P.; Basile, Maria Luisa; Longo, F.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - STAMPA. - 23:2(2011), pp. 110-113. [10.1179/joc.2011.23.2.110]
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer
Marisa Di Seri;R. De Sanctis;S. Quadrini;D. Adua;L. Stumbo;E. Del Signore;B. Gori;P. Grassi;Maria Luisa Basile;
2011
Abstract
The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with metastatic breast cancer (MBC). 51 patients with MBC received oral vinorelbine and capecitabine. The safety profile was analyzed through NCI-CTCAE v3.0 and response was evaluated using RECIST criteria. The overall response rate was 37.2%: there were four complete responders (8%) and fifteen partial responders (29.4%); practically all the responders were patients previously treated with anthracyclines and taxanes. Sixteen patients (31.3%) experienced stable disease. The clinical benefit rate was 68.5%. The median time to progression was 8 months (range 2-43; 95% Cl: 6-10.8). Vinorelbine in combination with capecitabine is an effective and safe schedule for patients with MBC especially after pretreatment with anthracycline/taxane-based regimens. The clinical benefit suggests that this may be a promising schedule in the MBC initial treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
